Pipeline
ABL503
HomePipelineABL503
-
- Pipeline
- ABL503
-
- Program Target
- PD-L1 x 4-1BB
-
- Disease Indication
- Solid Tumor
-
- Development Stage
- Clinical Development
(Phase 1)
- Summary
- ABL503 is a bispecific antibody that combines the capabilities of PD-L1 checkpoint pathway inhibiton with 4-1BB agonistic activity to overcome the specific limitations of PD-(L)1 immunotherapy and 4-1BB related toxicity. ABL503 is uniquely designed to only induce 4-1BB signalling when simultaneously binded to the PD-L1 tumor antigen on cancer cells, limiting the toxicity characteristic of traditional 4-1BB based treatment while augmenting T-cell activation. ABL503 shows superior anti-tumor activity in an animal model system compared to PD-L1 alone, 4-1BB alone, and the combination of PD-L1 and 4-1BB, with immunological memory resistant to any possible recurrence of the tumor.
Structure and Mechanism of Action
PD-L1 Dependent 4-1BB Activation
Superior Anti-Tumor Effect with Immunological Memory
Pharmacodynamic changes along with anti-tumor effect
Superior activity over Atezolizumab
Publications
| Pipeline | Journal | Date | Title | Link | |
|---|---|---|---|---|---|
| ABL503 | JITC | 2021 | Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade |  |
 |
Posters
| Pipeline | Name | Title | |
|---|---|---|---|
| ABL503 | SITC | ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment | |
| PEGS 2019 | The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation | |